#### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: O82088

Atsuro NAKAZATO, et al. Allowed: April 24, 2006

Appln. No.: 10/500,101 Group Art Unit: 1621

Confirmation No.: 2771 Examiner: Paul A. Zucker

Filed: June 25, 2004

For: 6-FLUOROBICYCLO [3.1.0] HEXANE DERIVATIVES

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

### MAIL STOP ISSUE FEE

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notities the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003. INFORMATION DISCLOSURE STATEMENT Attorney Docket No.: O82088

U.S. Appln. No.: 10/500,101

The present Information Disclosure Statement is being filed after either a Final Office Action, Notice of Allowance, or an action that otherwise closes prosecution in the application (whichever is earlier), but before payment of the Issue Fee, and therefore Applicant authorizes the USPTO to charge the fee of \$180.00 to Deposit Account No. 19-4880 under

37 C.F.R. § 1.17(p), and submits herewith a Statement Under 37 C.F.R. § 1.97(e).
The present Information Disclosure Statement is being filed thirty days or fewer from the communication from a foreign patent office and, therefore, a Statement Under

37 C.F.R. §1.704(d) is attached.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

23373

Date: April 27, 2006

### PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q82088

Atsuro NAKAZATO, et al.

Appln. No.: 10/500,101 Group Art Unit: 1621

Confirmation No.: 2771 Examiner: Paul A. Zucker

Filed: June 25, 2004

For: 6-FLUOROBICYCLO [3.1.0] HEXANE DERIVATIVES

STATEMENT UNDER 37 C.F.R. § 1.704(d)

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 Sir:

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and that the communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filling of said Information Disclosure Statement.

Respectfully submitted.

Registration No. 30.951

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

23373

Date: April 27, 2006

### PATENT APPLICATION

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q82088

Atsuro NAKAZATO, et al.

Appln. No.: 10/500,101 Group Art Unit: 1621

Confirmation No.: 2771 Examiner: Paul A. Zucker

Filed: June 25, 2004

For: 6-FLUOROBICYCLO [3.1.0] HEXANE DERIVATIVES

STATEMENT UNDER 37 C.F.R. § 1.97(e)

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

Sir

The undersigned hereby states, upon information and belief:

That each item of information contained in the Information Disclosure Statement filed concurrently herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of said Information Disclosure Statement.

Respectfully submitted.

Registration No. 30,951

SUGHRUE MION, PLLC Telephone: (202) 293-7060 Facsimile: (202) 293-7860

23373

Date: April 27, 2006

Substitute for Form 1449 A & B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Sheet 1 of 1

Application Number 10/500 101 Confirmation Number June 25, 2004

Attorney Docket Number

Filing Date First Named Inventor Atsure NAKAZATO Art Unit 1621 Paul A. Zucker Examiner Name

Complete if Known

O82088

HE BATENT DOCUMENTS

U.S. FATENT BOCUMENTS										
Examiner Initials*	Cite No.1	Document Number		Publication Date						
		Number	(tf known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document					
		US 5.958.960		09-28-1999	Massey, et al.					
		US 2002/193367	Al	12-19-2002	Adam Goo, et al.					
		US								
		US								
		US								
		US								
		US								
		US								

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.3	Foreign Patent Document		Publication Date	Name of Patentee or		
		Country Code <sup>3</sup>	Number <sup>4</sup>	Klad Code* (of known)	MM-DD-YYYY	Applicant of Cited Document	Translation <sup>6</sup>
		WO	01/02342	A	01-11-2001	IGT PHARMA INC.	
		WO	01/85669	Al	11-15-2001	Kenneth Curry	

NON PATENT I ITERATURE DOCUMENTS

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tide of the article (when appropriate), tide of the item (book, maganne, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>		

Examiner Signature

<sup>\*</sup>EXAMINER Initial if reference considered, whether or not ediation as in configuration with MPEP 609. Draw line through existion of not in configuration and not considered. Include, edge of this form with next communication to applicant

Applicant's arrays custom designation number (options). "See Kind Codes of USPTO Patient December's in www signing say, MPEP 901 60 of folios the hyperlisk from the tide of the document to the intrince." I time of the collection of the custom is the consent, by the two-kinds code (WHO Summled SE. 3). "Far I passes, private document, where the distants of the expert of the private in the custom is a studied on the clearness under WHO summer and SE. "The distants of the custom is a student of the clearness under WHO summer and SE. I for provide," " Applicant is to indicate here if English language Translation is attached